Today, many clinical trials don’t meet their deadlines. While many life sciences companies are leveraging data to help support their trial feasibility decisions, few have made it a priority to consistently implement and automate the use of data in those decisions—a potentially costly oversight. In this article, ZS experts present seven building blocks that will help life sciences companies make evidence-based, end-to-end feasibility decisions to improve their clinical trial efficiency.
- How epidemiological data can help you find eligible trial patients
- Why mapping the KOL landscape is essential to effective site selection
- How to choose investigators that are participating in complementary rather than competitive trials